![]() ![]() Safety and efficacy have not been established. For non-prescription products, read the label or package ingredients carefully.Īppropriate studies have not been performed on the relationship of age to the effects of apixaban in the pediatric population. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. ![]() For this medicine, the following should be considered: Allergies This is a decision you and your doctor will make. In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This product is available in the following dosage forms: This medicine is available only with your doctor's prescription. It works by decreasing the clotting ability of the blood and helps preventing harmful clots from forming in the blood vessels. "Apixaban and atrial fibrillation. No clear advantage" Prescrire Int 2014 23 (146): 33-36.Apixaban is also used to prevent stroke and blood clots in patients with certain heart rhythm problem (eg, nonvalvular atrial fibrillation).Īpixaban is a factor Xa inhibitor, an anticoagulant. When the INR cannot be maintained within the desired therapeutic range, it is best to stick with dabigatran. In practice, the antithrombotic treatment of choice for patients with atrial fibrillation is warfarin when the risk of thrombosis is high, and warfarin or aspirin when the thrombotic risk is moderate.In addition, the anticoagulant action of apixaban is increased by renal failure, meaning that renal function must be regularly monitored. Apixaban is a substrate for various cytochrome P450 isoenzymes and for P-glycoprotein, creating a risk of multiple drug-drug interactions.In 2013, there is no way of monitoring the anticoagulant activity of apixaban in routine clinical practice, and there is no antidote in case of overdose the same is true for dabigatran.In clinical trials, major bleeding events were less frequent with apixaban than with warfarin (average 2.1 versus 3.1 events per 100 patient-years), but they were more frequent with apixaban than with aspirin (1.4 versus 0.9 events per 100 patient-years).A double-blind, randomised trial including 5598 patients compared apixaban with aspirin but provided little information on these options in patients with a moderate risk of thrombosis, as most patients were at high risk.Clinical evaluation included no trials comparing apixaban with dabigatran any indirect comparison would be risky given the poor quality of the clinical assessment of both drugs in atrial fibrillation.In addition, these results are undermined by multiple methodological flaws. ![]() This difference was mainly due to a lower incidence of haemorrhagic stroke and did not result in a clear decline in mortality. ![]() In a double-blind, randomised non-inferiority trial versus warfarin in 18 201 patients, the incidence of stroke or systemic embolism was lower in the apixaban group (average 1.3 versus 1.6 events per 100 patient-years p = 0.01).Apixaban, a factor Xa inhibitor anticoagulant, has been authorised in the European Union for use in patients with non-valvular atrial fibrillation and a moderate or high risk of thrombosis.Patients with a moderate thrombotic risk may receive either warfarin or low-dose aspirin. Dabigatran, a thrombin inhibitor, is the alternative when warfarin fails to maintain the INR within the therapeutic range. For the prevention of thromboembolic events in patients with atrial fibrillation and a high thrombotic risk, the standard treatment is warfarin, an anticoagulant. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |